We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.
- Authors
Peggs, K. S.; Quezada, S. A.; Allison, J. P.
- Abstract
The generation and maintenance of immune responses are controlled by both co-stimulatory and co-inhibitory signalling through T cell co-receptors, many of which belong to the immunoglobulin-like superfamily or the tumour necrosis factor receptor superfamily. Agonistic or antagonistic monoclonal antibodies targeting these co-receptors have the potential to enhance immunity. Furthermore, their activity on the immunosuppressive regulatory T cell populations which are prevalent within many tumours provides an additional rationale for their use as anti-cancer therapies. This review summarizes the interactions between cancer and the immune system, highlighting the ways in which these new classes of immunostimulatory antibodies might enhance anti-tumour immunity and summarizing early clinical experience with their use.
- Subjects
CANCER immunotherapy; CELL receptors; NECROSIS; T cell receptors; IMMUNOSUPPRESSION
- Publication
Clinical & Experimental Immunology, 2009, Vol 157, Issue 1, p9
- ISSN
0009-9104
- Publication type
Article
- DOI
10.1111/j.1365-2249.2009.03912.x